Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Ametantrone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.59 |
| ▸ | MC4R known ✓ | P32245 | 1/20 | 0.59 |
| ▸ | OPRK1 known ✓ | P41145 | 1/20 | 0.59 |
| ▸ | SCN5A known ✓ | Q14524 | 1/20 | 0.59 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.86 |
| ▸ | MEN1 | O00255 | 4/20 | 0.61 |
| ▸ | BLM | P54132 | 4/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.61 |
| ▸ | NSD2 | O96028 | 3/20 | 0.61 |
| ▸ | POLB | P06746 | 3/20 | 0.61 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.59 |
| ▸ | LMNA | P02545 | 4/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.59 |
| ▸ | HTT | P42858 | 4/20 | 0.59 |
| ▸ | RECQL | P46063 | 3/20 | 0.59 |
| ▸ | USP2 | O75604 | 2/20 | 0.59 |
| ▸ | TP53 | P04637 | 2/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.59 |
| ▸ | NPC1 | O15118 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ametantrone SCHEMBL31237396 | 1.00 | TOP2B (0.86) | TOP2BMEN1BLMKMT2ANSD2 | |
| Ametantrone SCHEMBL29899532 | 1.00 | TOP2B (0.86) | TOP2BMEN1BLMKMT2ANSD2 | |
| Ametantrone SCHEMBL3344151 | 0.93 | TOP2B (1.00) | TOP2BMEN1BLMKMT2ANSD2 | |
| Ametantrone SCHEMBL29723071 | 0.93 | TOP2B (1.00) | TOP2BMEN1BLMKMT2ANSD2 | |
| Hydrochloric Acid SCHEMBL11041980 | 0.91 | TOP2B (0.97) | TOP2BMEN1BLMKMT2ANSD2 | |
| SCHEMBL18567079 | 0.86 | TOP2B (0.86) | TOP2BMEN1BLMKMT2ANSD2 | |
| SCHEMBL15277979 | 0.84 | TOP2B (0.83) | TOP2BMEN1BLMKMT2ANSD2 | |
| SCHEMBL15271304 | 0.84 | TOP2B (0.83) | TOP2BMEN1BLMKMT2ANSD2 | |
| SCHEMBL1426702 | 0.83 | TOP2B (0.81) | TOP2BMEN1BLMKMT2ANSD2 | |
| SCHEMBL29357976 | 0.83 | TOP2B (0.81) | TOP2BMEN1BLMKMT2ANSD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 9017 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116861-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-04-30 | — | — | US | claimed |
| US-12522572-B2 | Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-01-13 | — | — | US | claimed |
| EP-4524131-A1 | SMALL MOLECULES FOR TREATING CANCER, INHABITING CHEMOKINE ACTIVITY AND/OR INDUCING CELL DEATH | AlonBio Ltd. (IL) | 2025-03-19 | — | — | EP | claimed |
| US-12202803-B2 | Small molecules for treating cancer, inhibiting chemokine activity and/or inducing cell death | ALONBIO LTD. (IL) | 2025-01-21 | — | — | US | claimed |
| US-20240343697-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2024-10-17 | — | — | US | claimed |
| US-12109219-B2 | Cannabinoid receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2024-10-08 | — | — | US | claimed |
| WO-2024162488-A1 | PHARMACEUTICAL COMPOSITION COMPRISING CUCURBITACIN D FOR PREVENTING OR TREATING NEUROPATHIC PAIN | 주식회사 재인알앤피 | 2024-08-08 | — | — | WO | claimed |
| EP-4401780-A1 | AMORPHOUS PHOTOSENSITIZING PARTICLES, METHODS FOR THE PREPARATION THEREOF, AND METHODS FOR THE USE THEREOF | University of Maryland, College Park (US) | 2024-07-24 | — | — | EP | claimed |
| WO-2024026505-A2 | DISRUPTION OF TELOCYTE ACTIVITY | PATEL AMIT (US) | 2024-02-01 | — | — | WO | claimed |
| US-20240002347-A1 | SMALL MOLECULES FOR TREATING CANCER, INHIBITING CHEMOKINE ACTIVITY AND/OR INDUCING CELL DEATH | ALONBIO LTD. (IL) | 2024-01-04 | — | — | US | claimed |
| WO-2008062466-A2 | CINNAMIC ACID, VANILLIC ACID AND BENZOFURAN DERIVATIVES FOR USE IN THE TREATMENT OF INFLAMMATION AND CANCER | RELIANCE LIFE SCIENCES PVT. LTD. (IN) | 2008-05-29 | — | — | WO | claimed |
| WO-2008039254-A2 | RNA NANOPARTICLES AND NANOTUBES | GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2008-04-03 | — | — | WO | claimed |
| WO-2007059116-A2 | GELDANAMYCIN DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF | ABRAXIS BIOSCIENCE, INC. (US) | 2007-05-24 | — | — | WO | claimed |
| US-20060079472-A1 | Methods for treating angiogenesis | ANGIOSYN, INC. | 2006-04-13 | — | — | US | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20040092583-A1 | Treatment for inhibiting neoplastic lesions | SHANAHAN-PRENDERGAST ELIZABETH (IE) | 2004-05-13 | — | — | US | claimed |
| EP-1351678-A2 | TREATMENT FOR INHIBITING NEOPLASTIC LESIONS USING INCENSOLE AND/OR FURANOGERMACRENS | Shanahan-Prendergast, Elizabeth (IE) | 2003-10-15 | — | — | EP | claimed |
| WO-2002053138-A2 | TREATMENT FOR INHIBITING NEOPLASTIC LESIONS USING INCENSOLE AND/OR FURANOGERMACRENS | SHANAHAN-PRENDERGAST ELISABETH (IE) | 2002-07-11 | — | — | WO | claimed |